Recent Updates
Recently added Catalysts

V951A

Phase 1

Undisclosed | Biologics | Other |Merck & Company, Inc.|Trials Updated: Nov 16, 2026

V951A development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment252

FDA Designations

No designations recorded

V951A clinical trials

V951A · 1 trial · 1 indication

Phase 1 1
NCT07939399A Study of V951A in Healthy Participants (V951A-001)Healthy Volunteers
NOT YET_RECRUITING252 Analytics
PHASE1NOT YET_RECRUITING
A Study of V951A in Healthy Participants (V951A-001)
Healthy VolunteersUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants With Solicited Injection-Site Adverse Events (AE)
Up to 7 days after each vaccination

An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited injection-site AEs are predetermined local reactions at the injection site (such as pain/tenderness, erythema/redness, and swelling) recorded on the participant's electronic diary card.

Percentage of Participants with Solicited Systemic AE
Up to 7 days after each vaccination

An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited systemic AEs are predetermined body-wide reactions (such as headache, fever, fatigue, myalgia/muscle pain, and arthralgia/joint pain) recorded on the participant's electronic diary card.

Percentage of Participants with Immediate Post-Vaccination AEs
Up to 30 minutes after each immunization

This measures specific body-wide side effects monitored closely (typically fever, headache, fatigue, muscle pain, and joint pain).

Percentage of Participants with Unsolicited AEs
Up to 28 days after each immunization

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. Unsolicited AEs are any unexpected, non-predetermined medical events reported by the participant that are not specifically listed on the daily diary card.

Percentage of Participants with Serious Adverse Events (SAEs)
Up to approximately 18 months

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A Serious Adverse Event (SAE) is any AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event that may jeopardize the participant.

Percentage of Participants with Medically Attended AEs (MAAEs)
Up to approximately 18 months

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A MAAE is defined as any AE that results in an unscheduled visit to a healthcare professional (such as a physician's office, clinic, or emergency room) for medical evaluation or treatment.

Percentage of Participants with Adverse Events of Special Interest (AESIs)
Up to approximately 18 months

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. An AESI is a noteworthy medical event of clinical interest (such as a severe allergic reaction or specific neurological event) that has been designated for expedited tracking and continuous safety surveillance within this vaccine clinical program.

Secondary Endpoints

Geometric Mean Concentration (GMC) of V951A-Specific Antibodies
At designated time points and up to up to approximately 18 months
Percentage of Participants Achieving Seroconversion to V951A
At designated time points and up to up to approximately 18 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
V951A Group AEXPERIMENTALHealthy younger adult participants (typically aged 18 to 49) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in a younger population.
V951A Group BEXPERIMENTALHealthy older adult participants (typically aged 50 and older) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in an older population.
PlaceboPLACEBO_COMPARATORHealthy adult participants who will receive placebo injections containing no active vaccine. This group acts as a comparator to help researchers safely evaluate the effects of the active investigational vaccine.

Interventions

NameTypeDescription
V951ABIOLOGICALAdministered via intramuscular injection.
PlaceboOTHERAdministered via intramuscular injection.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 79 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Good General Health: Is in good health as determined by medical history, physical examination, vital signs, and clinical laboratory evaluations prior to study dosing. * Body Mass Index (BMI): Has a BMI within the range of 18.0 to 32.0 kg/m² (inclusive) at the time of screening...

Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 16, 2026NCT07939399NEW_TRIAL: changed
LOWNov 16, 2026NCT07939399NEW_TRIAL: changed